AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Pharma company offers data on Yondelis and Aplidin at conference.
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- PharmaMar presented new data from its two lead drugs, Yondelis and Aplidin, at the 29th European Society for Medical Oncology Congress (ESMO) held in Vienna, Austria.
Data from two separate studies in patients with solid tumors using Yondelis in combination with the chemotherapy drugs Doxil/Caelyx and carboplatin were presented. The combination of Yondelis with Doxil was shown to be safe and feasible. These trials form the basis for the future development of Yondelis in ovarian cancer as well as in other tumors.
New data was also presented from the preliminary results of a phase II study in Aplidin, which demonstrated evidence of Aplidin's activity in patients with advanced or metastatic melanoma.
The phase I study of Yondelis in combination with Doxil indicates that the combination of Yondelis plus Doxil/Caelyx is well tolerated and feasible, thus allowing the delivery of therapeutic doses of both compounds. Partial responses (reductions in tumor sizes) were observed in patients with ovarian and head and neck cancers as well as in soft tissue sarcomas.
The phase I combination study of Yondelis and carboplatin in advanced solid tumors study's goal of this study is to determine the recommended dose of Yondelis in combination with carboplatin. Preliminary evidence of antitumoral activity has been observed in this trial, although additional clinical research is ongoing.
The preliminary results of a phase II study of Aplidin as a second line therapy in patients with advanced or metastatic melanoma concluded that Aplidin showed activity as a single agent against melanoma in patients previously treated, with an acceptable safety profile. Dr Timothy Eisen, study investigator, concludes that further development of Aplidin in this disease is warranted.
In addition to these presentations of new data, previously reported data were also presented at ESMO, including Yondelis combinations with two other chemotherapy drugs, cisplatin and paclitaxel, a compassionate use programme in Italy, and a pharmacogenomics study on Yondelis.
- Pharma company offers data on Yondelis and Aplidin at conference.
- Newspaper article from: Clinical Oncology Week November 29, 2004 700+ words
...its two lead drugs, Yondelis and Aplidin, at the 29th European...demonstrated evidence of Aplidin's activity in patients...The phase I study of Yondelis in combination with...two lead compounds, Yondelis and Aplidin, give us further encouragement...
- Zeltia provides additional Yondelis data after EMEA blow.
- Newspaper article from: Pharma Marketletter July 21, 2003 700+ words
...its key cancer drug candidate Yondelis (ET-743) after the European...in Washington, USA, showed Yondelis may have utility in fighting...Marketletters passim). Yondelis aside, Zeltia said Aplidin, currently in Phase II trials...
- EC Awards Aplidin(R) Orphan Drug Status for Acute Lymphoblastic Leukaemia...
- Press release article from: PR Newswire July 17, 2003 700+ words
...weeks. Mechanisms of action Aplidin induces rapid and persistent...diverse mechanisms differentiates Aplidin from other known anticancer...portfolio currently includes Yondelis(TM), co-developed with OrthoBiotech Products L.P., Aplidin(R), Kahalalide F and ES...
- PharmaMar Reports Phase I Results for Yondelis in Combination with Cisplatin.
- Press release article from: PR Newswire November 14, 2003 700+ words
...pharmacokinetic activity of Yondelis(TM) when used in...examining the activity of Aplidin(r) in neuroendocrine...The Phase I study of Yondelis in combination with...portfolio currently includes Yondelis(TM) (co-developed...ovarian cancer in 2003; Aplidin(r), designated Orphan...
- Data on two antitumor agents reported.(Aplidin study results)
- Newspaper article from: Cancer Weekly November 19, 2002 700+ words
...its second lead compound, Aplidin (APL), in both medullary...outcomes from a phase II study of Yondelis (ET-743) in ovarian cancer...trial for the evaluation of Aplidin in MTC is now being developed...concerned with the development of Aplidin in pediatric leukemia were...
- Aplidin(R) Commences Combination Trials.
- Press release article from: PR Newswire Europe September 15, 2005 700+ words
...be particularly sensitive to Aplidin. There is no evidence of cross...haematological malignancies. Aplidin(R) shows no clinical evidence...portfolio currently includes: YONDELIS(R) (co-developed with...in 2005. It also features Aplidin(R), in Phase II, designated...
- Aplidin Enters Phase I Trials In Paediatric Solid Tumours and Leukaemias.
- Press release article from: PR Newswire March 22, 2004 700+ words
...VEGFR1). Reference: 1. Aplidin(r) is the registered trademark of Aplidin. PharmaMar PharmaMar is a...portfolio currently includes Yondelis (TM) in phase II/III clinical...for ovarian cancer in 2003; Aplidin(r), in phase II, designated...
- Aplidin Phase II Trial Update.
- Press release article from: Business Wire May 10, 2004 700+ words
...receptor 1 (VEGFR1). *Aplidin(R) is the registered trademark of Aplidin. PharmaMar PharmaMar is a...portfolio currently includes Yondelis(TM) in phase II/III clinical...for ovarian cancer in 2003; Aplidin(R), in phase II, designated...
